Oral GLP-1 Formulation via Intestinal Absorption Adjuvants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GLP-1 receptor agonists for type 2 diabetes, primarily administered via injection, are inconvenient and cause pain, necessitating a change in administration route to improve patient compliance and efficacy.
Innovation Solution
A pharmaceutical composition comprising a GLP-1 receptor agonist combined with a novel absorption-promoting mixture of sodium lauryl sulfate, carbomer, chitosan, and sodium citrate, which enhances small-intestinal absorption, allowing for an oral formulation that was previously only available via injection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GLP-1 receptor agonists are administered via injection, then the drug delivery is effective and reliable, but the ease of operation deteriorates due to inconvenience and pain
Solution Approach 1:
The patent uses an absorption-promoting composition as an intermediary substance that facilitates the absorption of GLP-1 receptor agonists in the small intestine. This mediator enables oral administration by enhancing drug uptake without requiring injection, thus resolving the contradiction between reliable drug delivery and ease of operation.
Solution Approach 2:
The patent changes the administration route parameter from parenteral (injection) to oral by modifying the formulation with absorption-promoting agents. This parameter change enables the same drug to be effectively delivered through a different, more convenient route, resolving the contradiction between reliability and ease of operation.
2Ease of operation
If oral formulation is used, then the ease of operation improves, but the bioavailability deteriorates due to poor absorption
Solution Approach 1:
The absorption-promoting composition acts as an intermediary that enhances the absorption of orally administered GLP-1 receptor agonists in the small intestine. This mediator resolves the contradiction by enabling effective oral delivery without sacrificing bioavailability.
Solution Approach 2:
The patent creates a composite formulation combining GLP-1 receptor agonists with absorption-promoting substances (sodium lauryl sulfate, carbomer, chitosan, and sodium citrate). This composite material achieves both oral administrability and sufficient bioavailability, resolving the contradiction between ease of operation and quantity of substance absorbed.
3Quantity of substance
If absorption-promoting composition is added, then the bioavailability improves, but the device complexity increases
Solution Approach 1:
The patent modifies the formulation parameters by adding specific absorption-promoting substances to enhance bioavailability. While this increases formulation complexity, it enables oral administration with sufficient absorption, resolving the contradiction between bioavailability improvement and acceptable formulation complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly improves the bioavailability and hypoglycemic effect of GLP-1 receptor agonists, enabling effective oral administration and reducing the risk of cardiovascular complications in type 2 diabetes patients.
Implementation Method 1
a composition for promoting small-intestinal absorption, which comprises sodium lauryl sulfate, carbomer, chitosan, and sodium citrate
Data Source
AI summary
A pharmaceutical composition having a hypoglycemic effect, comprising: a GLP-1 receptor agonist, and a composition for promoting small-intestinal absorption; wherein the composition for promoting small-intestinal absorption comprises sodium lauryl sulfate, carbomer, chitosan, and sodium citrate. The composition for promoting small intestinal absorption according to the present invention may be prepared into a composite adjuvant, which, when combined with a GLP-1 agonist, can improve the absorption of this active ingredient in the small intestine and the like.